<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03103893</url>
  </required_header>
  <id_info>
    <org_study_id>1604004478</org_study_id>
    <nct_id>NCT03103893</nct_id>
  </id_info>
  <brief_title>Novel Compositions for Treating or Preventing Dermal Disorders</brief_title>
  <official_title>Novel Compositions for Treating or Preventing Dermal Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Drexel University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Drexel University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial examines the impact of a topical formulation of rapamycin on dermal thickness and&#xD;
      senescence.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aging of the skin is the most prominent feature of the aging process, being caused by&#xD;
      multiple factors such as intrinsic aging process and UV light exposure.&#xD;
&#xD;
      Dermal atrophy, also called skin atrophy or atrophy, is a disorder manifesting thinning or&#xD;
      depression of skin due to reduction of underlying tissue. Dermal atrophy is a major clinical&#xD;
      problem in the elderly population. Loss of dermal integrity leads to increased fragility of&#xD;
      the skin and precludes the use of intravenous lines in many cases. Skin tears are a&#xD;
      significant concern in elderly individuals directly related to dermal atrophy. Impairment in&#xD;
      wound healing is an important clinical sequelae of reduced dermal integrity leading to an&#xD;
      increase in the number of the infections and complications following injury. Seborrheic&#xD;
      keratosis, which comprise focal areas of epidermal thickening, can occur, possibly&#xD;
      representing a response to damage. It has been estimated that 100% of individuals over 50&#xD;
      years of age harbor at least one of these lesion. There is not treatment for dermal atrophy&#xD;
      and seborrheic keritoses require excision if they become large enough to cause discomfort or&#xD;
      distress.&#xD;
&#xD;
      Therefore, there is a need to develop novel compositions and methods for treating or&#xD;
      preventing certain age-related dermal conditions.&#xD;
&#xD;
      Rapamycin is an FDA approved drug that has been in clinical use for over 15 years. Systemic&#xD;
      application of rapamycin has been a central part of immuno suppressive therapy for transplant&#xD;
      patients in combination with other immuno suppressants. The safety record for systemic use of&#xD;
      rapamycin is excellent and few side effects are associated with extended use.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 25, 2017</start_date>
  <completion_date type="Actual">November 30, 2017</completion_date>
  <primary_completion_date type="Actual">November 30, 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Patients will apply lotions containing either rapamycin or vehicle to 2 distinct areas of sun exposed skin.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Clinical assessors are blinded to recruitment and treatment assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Dermal thickness</measure>
    <time_frame>6-8 months</time_frame>
    <description>dermal thickness as assessed by direct measurement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gene expression</measure>
    <time_frame>6-8 months</time_frame>
    <description>immunohistochemistry and gene expression analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seborrheic Keratosis</measure>
    <time_frame>6-8 months</time_frame>
    <description>clinical severity will be assess using a 1-5 rating scale of severity. Lesions will be evaluated for their progression over the treatment period relative to the known course of growth for Seborrheic Keratoses.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Dermal Atrophy</condition>
  <arm_group>
    <arm_group_label>Rapamycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rapamycin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rapamycin</intervention_name>
    <description>topical formulation</description>
    <arm_group_label>Rapamycin</arm_group_label>
    <other_name>sirolimus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adults&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Individuals with any chronic disease will be excluded from the study including those&#xD;
             with the following conditions:&#xD;
&#xD;
               -  Diabetes&#xD;
&#xD;
               -  Any type of Malignancy&#xD;
&#xD;
               -  Severe coronary artery disease&#xD;
&#xD;
               -  HIV infection&#xD;
&#xD;
               -  Hepatitis C or B&#xD;
&#xD;
               -  Any sign of skin disorder or disease aside from normal aging, dermal atrophy, or&#xD;
                  seborrheic keratoses.&#xD;
&#xD;
               -  Premenopausal women will be excluded&#xD;
&#xD;
               -  Patients taking the following medications will be excluded:&#xD;
&#xD;
               -  Cyclosporin&#xD;
&#xD;
               -  Calcium channel blockers: diltiazem, verapamil&#xD;
&#xD;
               -  Antifungal agents e.g. clotrimazole, fluconazole, itraconazole&#xD;
&#xD;
               -  Antibiotics: clarithromycin, erythromycin, rifampicin&#xD;
&#xD;
               -  Anticonvulsants: carbamazepine, phenobarbitone, phenytoin&#xD;
&#xD;
               -  Antinausea drugs e.g. metoclopramide&#xD;
&#xD;
               -  Other drugs e.g. danazol, protease inhibitors (e.g. for HIV and hepatitis C&#xD;
                  including ritonavir, indinavir, boceprevir, and telaprevir)&#xD;
&#xD;
               -  Grapefruit juice&#xD;
&#xD;
               -  St John's wort (Hypericum perforatum, hypericin)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Sell, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty member</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christina Chung, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Drexel University College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ibiyonu Lawrence, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Drexel University College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Drexel Dermatology</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19102-1101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 7, 2017</study_first_submitted>
  <study_first_submitted_qc>March 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2017</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

